All stock lists
CVS HEALTH Corp (New York Stock Exchange:CVS)
US · Delayed Price · Currency is USD
Also listed: CVS.DE, 0HRS.LHealthcare · Medical - Healthcare Plans
83.85+2.52 (+3.10%)
Market cap
$107B
Insider Score
Health Score
Analyst consensus
Listed since
Feb 21, 1973
Website
Insider Score
85/ 100
CVS Insider Score
Bullish1 qualifying trade · 1 insider · $2.00M bought in the last 90 days
Financial Health Score
Fair
From CVS’s reported statements · Q3 2026 (trailing 12 months)
Profitability11 / 20
Profitable, but on a thin margin.
- Revenue
- $420.61B
- Net income
- $11.05B
- Net margin
- 2.6%
Leverage4 / 20
Heavily indebted for what it earns.
- Total debt
- $75.30B
- Cash
- $11.74B
- Net debt / EBITDA
- 3.23x
Liquidity5 / 20
Owes more within a year than it holds to pay it.
- Current assets
- $79.39B
- Current liabilities
- $93.10B
- Current ratio
- 0.85
Cash generation14 / 20
The business funds itself from operations.
- Operating cash flow
- $18.71B
- Free cash flow
- $15.57B
- FCF margin
- 3.7%
Dilution & runway19 / 20
Not funding itself by issuing shares.
- Shares outstanding
- 1282.0M
- Share growth (1y)
- 1.0%
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
CVS Income Statement
| Fiscal Period | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 |
| Revenue | 108.40 B | 106.10 B | 100.43 B | 105.69 B | 102.87 B | 98.92 B |
| Revenue Growth (YoY) | 5.37 % | 7.26 % | 6.17 % | 8.17 % | 7.80 % | 8.42 % |
| Cost of Revenue | 93.50 B | 90.35 B | 84.80 B | 92.13 B | 89.06 B | 85.32 B |
| Gross Profit | 14.90 B | 15.75 B | 15.62 B | 13.57 B | 13.81 B | 13.59 B |
| SG&A Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| R&D Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 11.33 B | 11.05 B | 10.94 B | 11.46 B | 17.01 B | 11.21 B |
| Operating Income | 3.57 B | 4.70 B | 4.68 B | 2.11 B | -3.21 B | 2.38 B |
| Pretax Income | 2.85 B | 3.98 B | 3.94 B | 1.35 B | -3.48 B | 1.65 B |
| Tax Provision | 678.00 M | 982.00 M | 995.00 M | -1.57 B | 508.00 M | 634.00 M |
| Net Income | 2.17 B | 3.00 B | 2.94 B | 2.94 B | -3.98 B | 1.02 B |
| EPS (Basic) | 1.70 | 2.33 | 2.31 | 2.32 | -3.13 | 0.81 |
| EPS (Diluted) | 1.68 | 2.31 | 2.30 | 2.30 | -3.13 | 0.80 |
| Shares Outstanding | 1.28 B | 1.28 B | 1.27 B | 1.27 B | 1.27 B | 1.27 B |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.